CAR-T cells, re-directed to tumor-associated antigens (TAA), have shown promising results in clinical trials and some patients have even undergone complete tumor regression. However, current CAR-T cell therapy needs more careful balance between T-cell activation (ensure antitumor activity) and the potential of uncontrolled activation that may induce immunopathology. For example, rapid tumor cell clearance may induce cytokine release syndrome and tumor lysis syndrome, which are both dangerous complications during CAR-T therapy. On-target/off-tumor activation of CAR-T cells by low level expression of targets on non-malignant tissues has also been associated with many severe toxicity and even death in some cases. In order to control these adverse responses of T cell therapy, the Self-destruct CAR has been developed. Specifically, CAR-T cells are engineered to express self-destruct CAR through RNA electroporation or viral transduction. The self-destruct CAR plays as a molecular switch, which negatively controls the performance of T cell therapy through the elimination of CAR-T cells and further ensures the safety of T cell therapy. With a newly established platform to engineer T cells by RNA electroporation and viral transduction, Creative Biolabs provides the self-destruct CAR construction service for clients all over the world.
Self-destruct chimeric antigen receptor models and concepts
Nature Reviews Cancer. 2016.
The self-destruct CAR has exhibited potent antitumor effects and improved safety in preclinical xenograft models of human mesothelioma and advanced leukemia. The off switch suicide gene, herpes simplex virus thymidine kinase (HSV-TK), can be induced by ganciclovir and clear CAR-T cells after or during the gene therapy trials. Another suicide gene, inducible human caspase 9 (iCasp9), can also be induced by intravenous administration of FK506 binding protein (FK506BP) and remove CAR-T cells in animal experiments through apoptosis.
Creative Biolabs provides self-destruct CAR construction service for clients across the world. As a leading company in immunotherapy development, Creative Biolabs can provide various products and services related to CAR-T cell therapy. We provide services on the most advanced fourth generation CAR to work with our clients to develop more potent and safe CAR-T treatment methods.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE